Myocardial infarction drugs: Key market research findings
- Strategic alliances to help in the co-development and commercialization of drugs
- Extensive use of stent grafts to impel the prospects for market growth
Technavio has released a new market research report on the global myocardial infarction drugs market, which is expected to surpass $5 billion by 2020. The high prevalence of chronic conditions like hypertension, diabetes, and high cholesterol levels will result in the increased incidence of cardiovascular diseases. Due to this increase in the prevalence of chronic conditions, the number of individuals seeking medications for heart diseases is anticipated to rise dramatically. Furthermore, with the advent of new drugs during the forecast period, the growth prospects for this market will be high as the diagnosis and drug-treatment rates will increase.
The new industry research report from Technavio discusses in detail the key drivers and trends responsible for the growth of this market and its sub-segments.
“Strategic alliances, in terms of licensing and collaboration, help in the co-development and commercialization of drugs in different regions. Co-development agreements between different companies enable the use of technical expertise from both companies. It also ensures the inflow of adequate funds and reduces the cost of liability for the individual companies in case of failures. Such collaborations help to increase sales by bolstering the penetration of drugs in a particular market,” says Imran Mushtaq, Industry Manager, Pharma, Technavio Research
The widespread usage of stent grafts will aid in the growth of this market during the estimated period. Stenting has replaced open surgery as the first-line of treatment for many arterial occlusions as it is highly effective. The popularity of this procedure will increase further owing to advantages like accuracy in placement, ease of use, and effectiveness of navigation. Bioresorbable stents, which are designed to be absorbed by the body, are expected to become the primary interventional tool in the near future. Its ability to reduce the risk of late complications, such as thrombosis, and the need for long-term antiplatelet drugs will result in its augmented adoption during the forecast period.
The leading vendors in the global myocardial infarction drugs market are AstraZeneca, Bayer HealthCare, Eli Lilly, Novartis, Pfizer, and Sanofi. In this market, the vendors that have the capability to manufacture and market drugs that will effectively treat and cure myocardial infarction in patients will gain a competitive edge over their peers.
A more detailed analysis is available in the Technavio report, Global Myocardial Infarction Drugs Market 2016-2020.
We can customize reports by other regions and specific segments upon request.
Other related reports:
